Cargando…

Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis

 : Stopping smoking can considerably cut one's risk of developing cancer compared to continued smoking (i.e. up to 50% after 5 years for esophageal cancer and after 10 years for lung cancer). Much less is known about whether quitting smoking may bring a survival advantage to people who are acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Riccio, M, Bonaccorsi, G, Lorini, C, Vettori, V, Gandini, S, Caini, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834996/
http://dx.doi.org/10.1093/eurpub/ckac129.555
_version_ 1784868583264747520
author Del Riccio, M
Bonaccorsi, G
Lorini, C
Vettori, V
Gandini, S
Caini, S
author_facet Del Riccio, M
Bonaccorsi, G
Lorini, C
Vettori, V
Gandini, S
Caini, S
author_sort Del Riccio, M
collection PubMed
description  : Stopping smoking can considerably cut one's risk of developing cancer compared to continued smoking (i.e. up to 50% after 5 years for esophageal cancer and after 10 years for lung cancer). Much less is known about whether quitting smoking may bring a survival advantage to people who are active smokers at the time of cancer diagnosis. We conducted a systematic review and meta-analysis of the studies that examined the prognostic effect of quitting smoking at or around diagnosis among cancer patients. We searched MEDLINE and EMBASE for articles published until 30th March 2022 that reported the impact of quitting smoking at or around diagnosis on cancer patients’ survival (any type). Separately for each cancer site, study-specific data were pooled into summary relative risk (SRR) and corresponding 95% confidence intervals (CI) using random effect meta-analysis models, investigating sources of heterogeneity and bias. Forty-three articles were included, including 20 for lung cancer (LC), 16 for head and neck cancer (HNC), and less than 10 for bladder, breast, gastrointestinal tract, and other sites. Quitting smoking at or around diagnosis was associated with longer overall survival (SRR 0.71, 95% CI 0.64-0.80) in LC patients (consistently for non-small cell and small cell LC) as well as HNC patients (SRR 0.80, 95% CI 0.70-0.91). No significant publication bias was found. For the other body sites, the studies were limited in number, which prevented meta-analyses, but results were generally consistent with a beneficial effect of smoking cessation on survival. Quitting smoking at or around diagnosis is associated with a significantly improved overall survival of smokers diagnosed with LC and HNC and shows beneficial effects in patients with other cancers. Physicians should offer smoking cessation counselling to smokers who start diagnostic workup for suspected cancer, and smoking cessation strategies should arguably become part of standard multidisciplinary oncological care. KEY MESSAGES: • Smoking cessation at or around diagnosis is associated with a significantly improved overall survival of smokers diagnosed with different types of cancer. • Smoking cessation strategies (and counselling) should become part of standard multidisciplinary oncological care.
format Online
Article
Text
id pubmed-9834996
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98349962023-01-17 Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis Del Riccio, M Bonaccorsi, G Lorini, C Vettori, V Gandini, S Caini, S Eur J Public Health Parallel Programme  : Stopping smoking can considerably cut one's risk of developing cancer compared to continued smoking (i.e. up to 50% after 5 years for esophageal cancer and after 10 years for lung cancer). Much less is known about whether quitting smoking may bring a survival advantage to people who are active smokers at the time of cancer diagnosis. We conducted a systematic review and meta-analysis of the studies that examined the prognostic effect of quitting smoking at or around diagnosis among cancer patients. We searched MEDLINE and EMBASE for articles published until 30th March 2022 that reported the impact of quitting smoking at or around diagnosis on cancer patients’ survival (any type). Separately for each cancer site, study-specific data were pooled into summary relative risk (SRR) and corresponding 95% confidence intervals (CI) using random effect meta-analysis models, investigating sources of heterogeneity and bias. Forty-three articles were included, including 20 for lung cancer (LC), 16 for head and neck cancer (HNC), and less than 10 for bladder, breast, gastrointestinal tract, and other sites. Quitting smoking at or around diagnosis was associated with longer overall survival (SRR 0.71, 95% CI 0.64-0.80) in LC patients (consistently for non-small cell and small cell LC) as well as HNC patients (SRR 0.80, 95% CI 0.70-0.91). No significant publication bias was found. For the other body sites, the studies were limited in number, which prevented meta-analyses, but results were generally consistent with a beneficial effect of smoking cessation on survival. Quitting smoking at or around diagnosis is associated with a significantly improved overall survival of smokers diagnosed with LC and HNC and shows beneficial effects in patients with other cancers. Physicians should offer smoking cessation counselling to smokers who start diagnostic workup for suspected cancer, and smoking cessation strategies should arguably become part of standard multidisciplinary oncological care. KEY MESSAGES: • Smoking cessation at or around diagnosis is associated with a significantly improved overall survival of smokers diagnosed with different types of cancer. • Smoking cessation strategies (and counselling) should become part of standard multidisciplinary oncological care. Oxford University Press 2022-10-25 /pmc/articles/PMC9834996/ http://dx.doi.org/10.1093/eurpub/ckac129.555 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the European Public Health Association. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Parallel Programme
Del Riccio, M
Bonaccorsi, G
Lorini, C
Vettori, V
Gandini, S
Caini, S
Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
title Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
title_full Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
title_fullStr Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
title_full_unstemmed Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
title_short Smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
title_sort smoking cessation at diagnosis and cancer survival: systematic review and meta-analysis
topic Parallel Programme
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834996/
http://dx.doi.org/10.1093/eurpub/ckac129.555
work_keys_str_mv AT delricciom smokingcessationatdiagnosisandcancersurvivalsystematicreviewandmetaanalysis
AT bonaccorsig smokingcessationatdiagnosisandcancersurvivalsystematicreviewandmetaanalysis
AT lorinic smokingcessationatdiagnosisandcancersurvivalsystematicreviewandmetaanalysis
AT vettoriv smokingcessationatdiagnosisandcancersurvivalsystematicreviewandmetaanalysis
AT gandinis smokingcessationatdiagnosisandcancersurvivalsystematicreviewandmetaanalysis
AT cainis smokingcessationatdiagnosisandcancersurvivalsystematicreviewandmetaanalysis